Curaleaf Launches Hostile $4/Share Bid for Aurora Cannabis, 45% Premium
ACB sits 18% above its 52-week low of $2.56.
Summary
Curaleaf is going public with a hostile take-over bid for Aurora Cannabis, offering US$4.00 per share — a 45% premium to Aurora's 30-day VWAP. The consideration is 0.3463 Curaleaf shares plus US$0.75 cash, capped at US$5.00 if Curaleaf's stock surges. This follows two private approaches in June and July that Aurora's board refused to discuss. The combined entity would have over US$1.5B in LTM revenue and nearly US$350M in adjusted EBITDA, spanning 17 countries. For Aurora shareholders, the immediate premium is substantial, and the deal would give them exposure to Curaleaf's U.S. operations and potential regulatory catalysts. The bid puts pressure on Aurora's board to engage, and the market will now price in deal probability. Watch for Aurora's formal response and any competing bids.
Updates
· SEC 6-K — Aurora's board will form a special committee of independent directors to consider the proposal and says no decision has been made. Aurora also says the July 7 letter lacked detail on cash/share mix and that the current proposal's $5.00 cap is below its December 18, 2025 trading price.
At the time of this announcement, ACB was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $187.5M. The 52-week trading range was $2.56 to $6.67. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.